Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
ADVM's Cash-to-Debt is ranked higher than
68% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. ADVM: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ADVM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.74  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.92
ADVM's Equity-to-Asset is ranked higher than
89% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. ADVM: 0.92 )
Ranked among companies with meaningful Equity-to-Asset only.
ADVM' s Equity-to-Asset Range Over the Past 10 Years
Min: -8.98  Med: 0.92 Max: 0.96
Current: 0.92
-8.98
0.96
Interest Coverage No Debt
ADVM's Interest Coverage is ranked higher than
61% of the 463 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ADVM: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ADVM' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 2
Altman Z-Score: 1.95
Beneish M-Score: 13.56
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -7923.30
ADVM's Operating Margin % is ranked lower than
91% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -92.73 vs. ADVM: -7923.30 )
Ranked among companies with meaningful Operating Margin % only.
ADVM' s Operating Margin % Range Over the Past 10 Years
Min: -7923.3  Med: -4266.08 Max: -719.58
Current: -7923.3
-7923.3
-719.58
Net Margin % -7817.66
ADVM's Net Margin % is ranked lower than
91% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -81.52 vs. ADVM: -7817.66 )
Ranked among companies with meaningful Net Margin % only.
ADVM' s Net Margin % Range Over the Past 10 Years
Min: -7817.66  Med: -4441.26 Max: -1099.17
Current: -7817.66
-7817.66
-1099.17
ROE % -47.65
ADVM's ROE % is ranked lower than
55% of the 756 Companies
in the Global Biotechnology industry.

( Industry Median: -38.58 vs. ADVM: -47.65 )
Ranked among companies with meaningful ROE % only.
ADVM' s ROE % Range Over the Past 10 Years
Min: -48.59  Med: -40.54 Max: -23.6
Current: -47.65
-48.59
-23.6
ROA % -44.69
ADVM's ROA % is ranked lower than
59% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -33.01 vs. ADVM: -44.69 )
Ranked among companies with meaningful ROA % only.
ADVM' s ROA % Range Over the Past 10 Years
Min: -717.34  Med: -45.6 Max: -22.27
Current: -44.69
-717.34
-22.27
ROC (Joel Greenblatt) % -2975.99
ADVM's ROC (Joel Greenblatt) % is ranked lower than
73% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -496.85 vs. ADVM: -2975.99 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ADVM' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -45075  Med: -4399.65 Max: -2221.58
Current: -2975.99
-45075
-2221.58
GuruFocus has detected 4 Warning Signs with Adverum Biotechnologies Inc $ADVM.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ADVM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ADVM Guru Trades in Q1 2016

Paul Tudor Jones 19,422 sh (New)
Jim Simons 278,700 sh (+239.46%)
» More
Q2 2016

ADVM Guru Trades in Q2 2016

Chuck Royce 193,346 sh (New)
PRIMECAP Management 423,900 sh (New)
Jim Simons 735,137 sh (+163.77%)
Paul Tudor Jones Sold Out
» More
Q3 2016

ADVM Guru Trades in Q3 2016

Jim Simons 1,004,400 sh (+36.63%)
PRIMECAP Management 426,300 sh (+0.57%)
Chuck Royce 92,346 sh (-52.24%)
» More
Q4 2016

ADVM Guru Trades in Q4 2016

Chuck Royce Sold Out
PRIMECAP Management 425,600 sh (-0.16%)
Jim Simons 969,700 sh (-3.45%)
» More
» Details

Insider Trades

Latest Guru Trades with ADVM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:BCDA, AMEX:RNN, NAS:PIRS, NAS:CTIC, NAS:ZFGN, NAS:EGLT, NAS:AFMD, NAS:PSTI, NAS:CDTX, OTCPK:TBGNF, OTCPK:RNUGF, NAS:APEN, NAS:CNAT, NAS:VVUS, NAS:CORI, OTCPK:IMMVF, NAS:CDXC, NAS:PRQR, NAS:ATHX, OTCPK:CTIX » details
Traded in other countries:AVU.Germany,
Avalanche Biotechnologies Inc is a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases.

Adverum Biotechnologies Inc is a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases. The Company has leveraged next-generation gene therapy platform to create a pipeline of product candidates. Their product candidates are designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. The Company operates and manages its business as one reporting and operating segment, which is the business of developing and commercializing gene therapeutics. Th Companies competitors include companies like MeiraGTx, Dimension Therapeutics, Inc., Voyager Therapeutics, Audentes Therapeutics, AveXis, REGENXBIO Biosciences, 4D Molecular Therapeutics, Applied Genetic Technologies Corporation and uniQure. The Company is regulated by FDA.

Top Ranked Articles about Adverum Biotechnologies Inc

Value Screeners Identify Cheap Company Stocks Technology and health care sectors offer bargain investments
As discussed in a previous article, the value screeners offer helpful investing insights. Not only do the screeners list good company stocks in which to invest, they can also identify which stock markets are undervalued. Read more...

Ratios

vs
industry
vs
history
PB Ratio 0.50
ADVM's PB Ratio is ranked higher than
97% of the 975 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. ADVM: 0.50 )
Ranked among companies with meaningful PB Ratio only.
ADVM' s PB Ratio Range Over the Past 10 Years
Min: 0.41  Med: 0.83 Max: 8.97
Current: 0.5
0.41
8.97
PS Ratio 61.47
ADVM's PS Ratio is ranked lower than
77% of the 774 Companies
in the Global Biotechnology industry.

( Industry Median: 13.23 vs. ADVM: 61.47 )
Ranked among companies with meaningful PS Ratio only.
ADVM' s PS Ratio Range Over the Past 10 Years
Min: 33.94  Med: 104.62 Max: 1518.85
Current: 61.47
33.94
1518.85
EV-to-EBIT 1.00
ADVM's EV-to-EBIT is ranked higher than
81% of the 250 Companies
in the Global Biotechnology industry.

( Industry Median: 17.39 vs. ADVM: 1.00 )
Ranked among companies with meaningful EV-to-EBIT only.
ADVM' s EV-to-EBIT Range Over the Past 10 Years
Min: -25.8  Med: 0.7 Max: 3.1
Current: 1
-25.8
3.1
EV-to-EBITDA 1.01
ADVM's EV-to-EBITDA is ranked higher than
83% of the 274 Companies
in the Global Biotechnology industry.

( Industry Median: 15.67 vs. ADVM: 1.01 )
Ranked among companies with meaningful EV-to-EBITDA only.
ADVM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -25.9  Med: 0.7 Max: 3.1
Current: 1.01
-25.9
3.1
Current Ratio 22.76
ADVM's Current Ratio is ranked higher than
95% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. ADVM: 22.76 )
Ranked among companies with meaningful Current Ratio only.
ADVM' s Current Ratio Range Over the Past 10 Years
Min: 0.46  Med: 22.76 Max: 39.7
Current: 22.76
0.46
39.7
Quick Ratio 22.76
ADVM's Quick Ratio is ranked higher than
95% of the 820 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. ADVM: 22.76 )
Ranked among companies with meaningful Quick Ratio only.
ADVM' s Quick Ratio Range Over the Past 10 Years
Min: 0.46  Med: 22.76 Max: 39.7
Current: 22.76
0.46
39.7
Days Sales Outstanding 222.26
ADVM's Days Sales Outstanding is ranked lower than
91% of the 524 Companies
in the Global Biotechnology industry.

( Industry Median: 59.75 vs. ADVM: 222.26 )
Ranked among companies with meaningful Days Sales Outstanding only.
ADVM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 6.08  Med: 41.42 Max: 222.26
Current: 222.26
6.08
222.26

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 0.53
ADVM's Price-to-Net-Cash is ranked higher than
99% of the 652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.34 vs. ADVM: 0.53 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ADVM' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.52  Med: 0.99 Max: 8.36
Current: 0.53
0.52
8.36
Price-to-Net-Current-Asset-Value 0.53
ADVM's Price-to-Net-Current-Asset-Value is ranked higher than
99% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. ADVM: 0.53 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ADVM' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.52  Med: 0.99 Max: 8.31
Current: 0.53
0.52
8.31
Price-to-Tangible-Book 0.51
ADVM's Price-to-Tangible-Book is ranked higher than
98% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. ADVM: 0.51 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ADVM' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.5  Med: 0.97 Max: 8.22
Current: 0.51
0.5
8.22
Price-to-Median-PS-Value 0.59
ADVM's Price-to-Median-PS-Value is ranked higher than
78% of the 673 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. ADVM: 0.59 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ADVM' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.58  Med: 1 Max: 12
Current: 0.59
0.58
12
Earnings Yield (Greenblatt) % 100.48
ADVM's Earnings Yield (Greenblatt) % is ranked higher than
95% of the 1109 Companies
in the Global Biotechnology industry.

( Industry Median: -10.11 vs. ADVM: 100.48 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ADVM' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 32.5  Med: 96.3 Max: 916.3
Current: 100.48
32.5
916.3

More Statistics

Revenue (TTM) (Mil) $1.46
EPS (TTM) $ -3.16
Short Percentage of Float2.16%
52-Week Range $2.55 - 6.31
Shares Outstanding (Mil)42.06
» More Articles for ADVM

Headlines

Articles On GuruFocus.com
Value Screeners Identify Cheap Company Stocks Aug 29 2016 
5 of the Most Discounted U.S. Listed Net-Nets Mar 30 2016 
5 Deep Value or Net-Net Investment Ideas Feb 09 2016 
PRIMECAP's 3rd-Quarter Increases That Exceeded 100% Jan 13 2016 

More From Other Websites
Adverum Biotechnologies, Inc. :ADVM-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 Mar 21 2017
ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Other Events Mar 20 2017
Adverum Biotechnologies, Inc. :ADVM-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017 Mar 15 2017
ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... Mar 14 2017
Adverum Biotechnologies, Inc. Appoints Patrick Machado, J.D. to Board of Directors Mar 14 2017
ADVERUM BIOTECHNOLOGIES, INC. Financials Mar 14 2017
ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 10-K, Annual Report Mar 09 2017
Adverum Biotechnologies posts 4Q loss Mar 06 2017
Adverum Biotechnologies posts 4Q loss Mar 06 2017
ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 06 2017
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2016 Financial Results and Provides... Mar 06 2017
ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Mar 01 2017
Adverum (ADVM) to Post Q4 Earnings: What's in the Cards? Feb 27 2017
Adverum Biotechnologies to Present at Upcoming Investor Conferences Feb 21 2017
ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers Feb 14 2017
ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a... Feb 10 2017
ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers Feb 03 2017
Adverum Biotechnologies to Present At Phacilitate Cell & Gene Therapy World 2017 Jan 18 2017
Is KCAP Financial Inc (KCAP) A Good Stock to Buy? Dec 19 2016
Is Osiris Therapeutics, Inc. (OSIR) A Good Stock To Buy? Dec 18 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)